Gujarat Themis Biosyn Latest Share Price (GUJTHEM)
TODAY IN ONE LINE
GUJTHEM fell 1.7% on above-average volume (6.5x avg), lagging Nifty's 0.5% move, supported by recent strong earnings.
With a market cap of ₹4,377.13 Cr., it trades at a P/E of 91.57. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Gujarat Themis Biosyn flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Capital EfficiencyROCE of 17.9% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 17.4%
- ●Healthy Operating MarginsOPM is structurally strong at 45.6%
- ●High Promoter HoldingPromoters hold 70.9% skin-in-the-game
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 9.1% YoY
- ●Rising Receivables vs SalesReceivables grew 13.4% outpacing sales growth of -11.2%
Latest Gujarat Themis Biosyn News
What changed recently?
Recent events, corporate actions, and announcements.
Gujarat Themis Biosyn Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Gujarat Themis Biosyn Limited, framed against the sector median so the premium or discount is obvious at a glance.
Gujarat Themis Biosyn Limited trades at a P/E of 91.57× and P/B of 15.50×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Gujarat Themis Biosyn Limited technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for Gujarat Themis Biosyn Limited — derived from the latest tape, not yesterday's close.
Gujarat Themis Biosyn Limited last traded at ₹404.7 with an intraday range of ₹392–₹416.65 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹404.70| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 466.20 | +61.50 | +15.20% |
| R3 | 441.55 | +36.85 | +9.11% |
| R2 | 429.10 | +24.40 | +6.03% |
| R1 | 416.90 | +12.20 | +3.01% |
| PIVOT | 404.45 | -0.25 | -0.06% |
| CURRENT | 404.70 | — | — |
| S1 | 392.25 | -12.45 | -3.08% |
| S2 | 379.80 | -24.90 | -6.15% |
| S3 | 367.60 | -37.10 | -9.17% |
| S4 | 342.95 | -61.75 | -15.26% |
GUJTHEM is trading Above CPR, indicating Bullishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹400.05–₹409.95
Trading Inside opening range
Gujarat Themis Biosyn Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Gujarat Themis Biosyn Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Gujarat Themis Biosyn Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹4,377.13 Cr. and reported EPS of ₹4.26.
Gujarat Themis Biosyn segment analysis : revenue and profit mix.
Disclosed business segments at Gujarat Themis Biosyn with their share of revenue and profit, switchable between consolidated and standalone reporting.
Gujarat Themis Biosyn discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Gujarat Themis Biosyn Limited.
Our AI distills the core fundamental drivers supporting Gujarat Themis Biosyn Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Gujarat Themis Biosyn Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Operating margin 37.76% significantly exceeds peer median 23.3%, demonstrating superior cost control.
Net profit margin 28.15% ranks highest among pharmaceutical peers, indicating strong pricing power.
ROCE 17.90% and ROE 17.40% reflect efficient capital deployment and consistent returns.
Promoter holding 70.86% signals robust insider confidence and long-term commitment.
Niche API expertise in Rifamycin-S and Lovastatin creates switching costs and recurring revenue.
Key Risks.
P/E ratio 93.56x far exceeds peer median 34.7x, indicating significant overvaluation concerns.
Latest quarterly EPS declined 9.2% YoY despite revenue growth, signaling profit margin pressure.
Quarterly sales declined 7.62% recently, showing near-term demand weakness and growth deceleration.
Dividend yield 0.19% substantially below sector average, limiting income appeal for investors.
Free cash flow negative ₹348.11 Cr latest quarter limits capex and organic growth investment.
Flip Conditions.
Valuation risk. a P/E above 119 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.06. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 12% would indicate weaker capital compounding.
Gujarat Themis Biosyn Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Gujarat Themis Biosyn Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Gujarat Themis Biosyn Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Gujarat Themis Biosyn Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Gujarat Themis Biosyn Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Gujarat Themis Biosyn Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Gujarat Themis Biosyn Limited stood at 49.0% of traded volume, against a 20-day average of 55.8%.
Gujarat Themis Biosyn announcements: results, concalls, ratings, M&A.
Filings Gujarat Themis Biosyn sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Gujarat Themis Biosyn files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 107 documents below.
Shareholders meeting
Gujarat Themis Biosyn Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has submitted the Exchange a…
Shareholders meeting
Gujarat Themis Biosyn Limited has informed the Exchange regarding Proceedings of Extraordinary General Meeting held on August 22, 2026. Further, the…
Analysts/Institutional Investor Meet/Con. Call Updates
Gujarat Themis Biosyn Limited has informed the Exchange about Presentation and Transcript
Analysts/Institutional Investor Meet/Con. Call Updates
Gujarat Themis Biosyn Limited has informed the Exchange about Link of Recording
Copy of Newspaper Publication
Gujarat Themis Biosyn Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Investor Presentation
Investor Presentation
Gujarat Themis Biosyn dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Gujarat Themis Biosyn has declared, sequenced by announce and record date.
Gujarat Themis Biosyn corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Gujarat Themis Biosyn Limited: business, sector, key facts.
What Gujarat Themis Biosyn Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Gujarat Themis Biosyn Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: GUJTHEM, BSE: 506879.
Gujarat Themis Biosyn Limited (GUJTHEM) is an Indian pharmaceutical company specializing in the manufacturing of pharmaceuticals and medicinal chemicals. Its primary operations are focused within India, contributing to the domestic pharmaceutical market.
A significant part of GUJTHEM's business model involves providing bulk drug manufacturing services on a job work basis. This means the company produces active pharmaceutical ingredients (APIs) for other pharmaceutical companies, acting as a contract manufacturer rather than solely focusing on producing and selling its own branded products. This outsourcing model allows GUJTHEM to leverage its manufacturing capabilities to serve a broader range of clients.
The company's product portfolio includes several key APIs, highlighting its expertise in specific therapeutic areas. Rifamycin-S, an intermediate used in the creation of tuberculosis treatments, is a prominent example. The production of Rifamycin-O, another important intermediate, also features prominently. Lovastatin, a cholesterol-lowering drug, represents another significant product within GUJTHEM's range. This diverse product mix showcases the company's capabilities in producing different types of APIs for various pharmaceutical applications.
Established in 1981 and headquartered in Mumbai, GUJTHEM has a long history in the Indian pharmaceutical industry. Its long operational history suggests a degree of experience and established manufacturing processes. The location in Mumbai positions it strategically within a major economic and industrial hub of India, facilitating access to resources, talent, and markets.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B Blackbio DX (3BBLACKBIO) Share PricePeer
- Abbott India (ABBOTINDIA) Share PricePeer
- Acutaas Chemicals (ACUTAAS) Share PricePeer
- Anlon Healthcare (AHCL) Share PricePeer
- Amanta Healthcare (AMANTA) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Gujarat Themis Biosyn Limited (GUJTHEM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Gujarat Themis Biosyn Limited (GUJTHEM)?
The current share price of Gujarat Themis Biosyn Limited (GUJTHEM) is ₹404.70. Today, the stock has declined by ₹7.00 (1.7%), trading in a range of ₹392.00 to ₹416.65. The stock opened at ₹409.95 with a trading volume of 9,26,859 shares.
02Is Gujarat Themis Biosyn Limited stock a good investment for long-term?
Gujarat Themis Biosyn Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹4,377.13 Cr., P/E ratio of 91.57, ROE of 17.4%, and ROCE of 17.9%. The dividend yield stands at 0.19%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Gujarat Themis Biosyn Limited stock?
The 52-week high price of Gujarat Themis Biosyn Limited (GUJTHEM) is ₹479.00, while the 52-week low is ₹225.05. Currently trading at ₹404.70, the stock is 79.83% above its 52-week low and 15.51% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Gujarat Themis Biosyn Limited stock at the current price?
Whether to buy Gujarat Themis Biosyn Limited stock at ₹404.70 depends on multiple factors. The stock is currently trading with a P/E ratio of 91.57 and P/B ratio of 15.5. Today's performance shows a loss of 1.7%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Gujarat Themis Biosyn Limited and when is the next dividend?
Gujarat Themis Biosyn Limited offers a dividend yield of 0.19%, which means for every ₹100 invested at the current price of ₹404.70, you can expect to receive approximately ₹0.19 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Gujarat Themis Biosyn Limited?
Gujarat Themis Biosyn Limited's key financial metrics include: P/E Ratio: 91.57, P/B Ratio: 15.5, ROE: 17.4%, ROCE: 17.9%, Dividend Yield: 0.19%, EPS: ₹4.26, Book Value: ₹26.41, and Debt-to-Equity: 0.56. The company's market cap stands at ₹4,377.13 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Gujarat Themis Biosyn Limited stock performing today in the market?
Gujarat Themis Biosyn Limited stock opened at ₹409.95 and is currently trading at ₹404.70, showing a decline of ₹7.00 (1.7%). The intraday high is ₹416.65 and low is ₹392.00. The trading volume stands at 9,26,859 shares, indicating moderate market participation today.
08What is the P/E ratio of Gujarat Themis Biosyn Limited and what does it indicate?
Gujarat Themis Biosyn Limited has a Price-to-Earnings (P/E) ratio of 91.57, which means investors are willing to pay 91.57 for every ₹1 of earnings. With an EPS of ₹4.26, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Gujarat Themis Biosyn Limited (GUJTHEM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.